Effect Of Semaglutide In Coronary Atheroma Plaque

NCT05071417 on ClinicalTrials.gov · last registry update 2021-10-08

A small phase 3 — 120 participants, against a typical 424. Its estimated completion date, December 2024, has passed with no update to the record. Primary outcome, as filed: Plaque burden modification assessed by coronary CT and plaque quantification. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for cardiovascular disease, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Sponsor type: Other
Enrollment: 120
Started: 2021-11
Primary completion: 2024-12 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Plaque burden modification assessed by coronary CT and plaque quantification

Conditions studied

Atheroscleroses, Coronary

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.